Recently, immunotherapy has fundamentally altered the direction of tumor treatment; PDCD1/PDCD1 ligand 1 (PDCD1LG1) drugs have been applied in first-line clinical trials for GAC [56, 57]. Here, PDCD1 is linked to neoplasm.